ClinicalTrials.gg
CompletedNCT05004311Updated Sep 22, 2025

The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics

A Phase 1 interventional study of Cenerimod in Healthy and Renal Impairment, sponsored by Viatris Innovation GmbH. Completed at 1 site in Portugal. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-22.

Sponsored by Viatris Innovation GmbH (part of Viatris Inc.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Renal Insufficiency with a site in Portugal — 3 open to participants now, 4 under way, 1 of them phase 3. Renal Insufficiency · Portugal.

Enrollment
11th of 12
16 · median 555
Started
2021
the only one that year
Phase 1
3 of 14
1 open now
Registered
12th of 14
by date

Among the 14 studies in Renal Insufficiency with a site in Portugal, this one is the 11th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2021, is one of 3 in phase 1, and was the 12th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

3 of the 14 studies in Renal Insufficiency with a site in Portugal are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Renal Insufficiency with a site in Portugal, or all of them as a file.
02

Study summary

To investigate the PK of cenerimod in participants with severe renal impairment as compared to healthy control participants.

03

Conditions studied

  • Healthy
  • Renal Impairment

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed in a language understandable to the participant prior to any study-mandated procedure.
  • Women of must have a negative serum pregnancy test at screening, a negative urine pregnancy test on Day -1, and agree to consistently and correctly use a highly effective method of .
  • Women of non-childbearing potential.
  • of 18.0 to 35.0 kg/m2 (inclusive) at Screening
  • Negative SARS-CoV-2 reverse transcription polymerase chain reaction test on Day -1.

Additional inclusion criteria for participants with severe renal impairment

  • Estimated (eGFR) at screening using the Modification of Diet in Renal Disease formula less-than 30 mL/min/1.73 m2 for participants with renal impairment. The eGFR value should be confirmed on Day -1.
  • Systolic blood pressure (SBP) 100 to 180 mmHg, diastolic BP (DBP) 50 to 105 mmHg, and pulse rate 60 to 100 bpm (inclusive), on Day 1 pre-dose.
  • Stable concomitant medications for at least 3 weeks prior to screening and up to Day 1.
  • and alanine aminotransferase above the .
  • findings in clinical laboratory tests (hematology, clinical chemistry, and urinanalysis) except for those related to renal impairment at Screening and on Day-1.

Additional inclusion criteria for control participants

  • eGFR at Screening using the Modification of Diet in Renal Disease formula of ≥ 90 mL/min/1.73 m2.
  • SBP 90 to 139 mmHg, DBP 60 to 89 mmHg, and pulse rate 60 to 99 bpm, measured on the same arm, after 5 min in the supine position at screening and on Day 1 pre-dose.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women.
  • Participation in a clinical study involving study treatment administration within 3 months prior to screening or participation in more than 2 clinical studies within 1 year prior to Screening.
  • Previous exposure to cenerimod.
  • Known to any of the treatment formulation.
  • abnormalities on a 12-lead at Screening and Day -1.
  • Previous treatment with anti-arrhythmic medications of class Ia or III within 2 weeks or 5 half-lives, whichever is longer, prior to study treatment administration.
  • History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism, or excretion of the study treatment except for renal disease, appendectomy, herniotomy, or cholecystectomy.
  • and alanine aminotransferase above the .
  • Legal incapacity or limited legal capacity at Screening.

Additional exclusion criteria for participants with severe renal impairment:

  • Presence of severe cardiac disease.
  • End-stage renal disease that requires dialysis.
  • History of severe renal artery stenosis.
  • Serum potassium concentration > 5.5 mmol/L.
  • Presence of unstable diabetes mellitus.
  • Strict fluid restriction.
  • Clinically relevant findings in clinical laboratory tests (hematology, clinical chemistry, and urinalysis) except for those related to renal impairment at Screening and on Day -1.

Additional exclusion criteria for control participants

  • Clinically relevant findings on the physical examination at Screening.
  • Clinically relevant findings in clinical laboratory tests.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Group A (severe renal function impairment)

    Eight (8) participants with severe renal impairment.

    Drug: Cenerimod

  • Experimental
    Group B (healthy)

    Eight (8) control participants, matched to the 8 severe renal impaired participants enrolled in Group A.

    Drug: Cenerimod

Interventions

  • A single oral dose of 0.5 mg cenerimod will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions

    Also known as: ACT-334441

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curve (AUC) from time zero to time t of the last measured concentration above the limit of quantification (AUC0-t) of cenerimod

    Time frame: Total duration: up to 52 days

  2. Area under the plasma concentration-time curve (AUC from 0 to infinity) of cenerimod

    Time frame: Total duration: up to 52 days

  3. The maximum plasma concentration (Cmax) of cenerimod

    Time frame: Total duration: up to 52 days

  4. The time to reach Cmax (tmax) of cenerimod

    Time frame: Total duration: up to 52 days

  5. Terminal half-life (t½) of cenerimod

    Time frame: Total duration: up to 52 days

  6. Apparent oral clearance (CL/F) of cenerimod

    Time frame: Total duration: up to 52 days

  7. Extent of cenerimod protein plasma binding (PPB)

    Time frame: Total duration: up to 52 days

  8. Apparent volume of distribution (Vz/F) of cenerimod

    Time frame: Total duration: up to 52 days

Secondary outcomes

  1. Total lymphocyte count count.

    Time frame: Total duration: up to 66 days

  2. Change from baseline at each time point of measurement in electrocardiogram QT interval

    Time frame: Total duration: up to 66 days

  3. Change from baseline in body weight

    Time frame: Total duration: up to 66 days

  4. Change from baseline in systolic and diastolic blood pressure (in the supine position)

    Time frame: Total duration: up to 66 days

  5. Incidence of abnormal laboratory test results

    Time frame: Total duration: up to 66 days

07

Study locations

1 site
  • BlueClinical Phase 1 Hospital de Prelado
    Porto, 4250-449, Portugal
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Jul 2023, 22 months.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 22 months is above that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2021
First posted
Aug 13, 2021
StartActual
Sep 27, 2021
Primary completionActual
Jul 27, 2023
CompletionActual
Aug 10, 2023
Last update
Sep 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05004311
Responsible party
Sponsor
First posted
Aug 13, 2021
Start date
Sep 27, 2021
Primary completion
Jul 27, 2023
Completion
Aug 10, 2023
Last update
Sep 22, 2025

Study contacts

Clinical Trials
study director · Viatris Innovation GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cenerimod

Start the discussion